Literature DB >> 28774409

Animal models of HBV infection.

Maura Dandri1, Joerg Petersen2.   

Abstract

The mechanisms determining hepatitis B virus (HBV) persistence and pathogenesis are not fully elucidated, but appear to be multi-factorial. Current medication to repress viral replication is available; however, the unique replication strategies employed by HBV enable the virus to persist within the infected hepatocytes. Consequently, cure is rarely achieved. Progresses in HBV research and preclinical testing of antiviral agents have been limited by the narrow species- and tissue-tropism of the virus, the paucity of infection models available and the restrictions imposed by the use of chimpanzees, the only animals fully susceptible to HBV infection. Mice are not HBV permissive but major efforts have focused on the development of mouse models of HBV replication and infection, such as the generation of humanized mice. By presenting the different animal models available, this review will highlight the most important and clinically relevant findings that have been retrieved from the respective systems.
Copyright © 2017 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Animal models; Antiviral therapy; HBV-related viruses; Hepadnaviruses; Humanized mice; Immunopathogenesis

Mesh:

Substances:

Year:  2017        PMID: 28774409     DOI: 10.1016/j.bpg.2017.04.014

Source DB:  PubMed          Journal:  Best Pract Res Clin Gastroenterol        ISSN: 1521-6918            Impact factor:   3.043


  6 in total

Review 1.  More than just oncogenes: mechanisms of tumorigenesis by human viruses.

Authors:  Marta M Gaglia; Karl Munger
Journal:  Curr Opin Virol       Date:  2018-09-27       Impact factor: 7.090

2.  Activity of nucleic acid polymers in rodent models of HBV infection.

Authors:  Katrin Schöneweis; Neil Motter; Pia L Roppert; Mengji Lu; Baoju Wang; Ingo Roehl; Dieter Glebe; Dongliang Yang; John D Morrey; Michael Roggendorf; Andrew Vaillant
Journal:  Antiviral Res       Date:  2017-11-08       Impact factor: 5.970

3.  [Generation of a novel HBeAg transgenic mice using CRISPR/Cas9 technique].

Authors:  Rui Guo; Yi Tian; Xueyuan Jin; Haiyan Chen; Guihu Wang; Xiaozhong Huang; Burong Li; Zongfang Li; Jun Yang
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2019-09-30

Review 4.  Evolutionary biology of human hepatitis viruses.

Authors:  Andrea Rasche; Anna-Lena Sander; Victor Max Corman; Jan Felix Drexler
Journal:  J Hepatol       Date:  2018-11-23       Impact factor: 25.083

5.  Ongoing viral replication and production of infectious virus in patients with chronic hepatitis B virus suppressed below the limit of quantitation on long-term nucleos(t)ide therapy.

Authors:  Dara L Burdette; Scott Lazerwith; Jenny Yang; Henry L Y Chan; William E Delaney Iv; Simon P Fletcher; Tomas Cihlar; Becket Feierbach
Journal:  PLoS One       Date:  2022-04-01       Impact factor: 3.240

6.  Clinical stage drugs targeting inhibitor of apoptosis proteins purge episomal Hepatitis B viral genome in preclinical models.

Authors:  Michelle P Clark; Thao Huynh; Peter Revill; Marc Pellegrini; Gregor Ebert; Shringar Rao; Liana Mackiewicz; Hugh Mason; Shahla Romal; Michael D Stutz; Sang H Ahn; Linda Earnest; Vitina Sozzi; Margaret Littlejohn; Bang M Tran; Norbert Wiedemann; Elizabeth Vincan; Joseph Torresi; Hans J Netter; Tokameh Mahmoudi
Journal:  Cell Death Dis       Date:  2021-06-23       Impact factor: 8.469

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.